50
Participants
Start Date
June 1, 2023
Primary Completion Date
April 30, 2025
Study Completion Date
June 30, 2025
fruquintinib
4 mg orally once daily, D1-14, repeated every 3 weeks.
Irinotecan
180 mg/m2, IV, day 1, repeated every 3 weeks. (Note: If patient has UGT1A1\*28 and \*6 as pure or double heterozygous variants, irinotecan dose 150 mg/m2, IV, day 1, repeated every 3 weeks, with close clinical observation).
Capecitabine
1000 mg/m2 orally twice daily, D1-14, repeated every 3 weeks.
RECRUITING
First Hospital of China Medical University, Shenyang
China Medical University, China
OTHER